Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-Human, Phase 1a, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, Single Ascending Dose Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of STAR-0310 in Healthy Adult Participants

Next Previous
Trial Profile

A First-in-Human, Phase 1a, Randomized, Double-Blind, Sponsor-Open, Placebo-Controlled, Single Ascending Dose Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of STAR-0310 in Healthy Adult Participants

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs STAR 0310 (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions; First in man; Proof of concept
  • Acronyms ALPHA-SOLAR
  • Sponsors Astria Therapeutics

Most Recent Events

  • 13 May 2025 According to an Astria Therapeutics media release, As of March 31, 2025, Astria had cash, cash equivalents and short-term investments of $295.1 million, compared to $328.1 million as of December 31, 2024. The Company expects that its cash, cash equivalents and short-term investments as of March 31, 2025 will be sufficient to fund its operations into mid-2027, including the completion of the ongoing Phase 1a clinical trial of healthy subjects.
  • 23 Jan 2025 According to Astria Therapeutics media release, company announced initiation of a Phase 1a clinical trial of STAR-0310 in healthy subjects. Company expects early proof-of-concept results from the Phase 1a trial in the third quarter of 2025.
  • 20 Jan 2025 Status changed from planning to recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top